Pharmaceutical Development Services and Schiff & Company form
alliance
11 August 2010
Schiff & Company Inc of New Jersey has joined forces with
Pharmaceutical Development Services Ltd (PDS) of Nottingham, UK, to
allow Schiff to offer PDS European regulatory expertise to its clients,
while PDS will benefit from the worldwide contacts that Schiff will
bring to the alliance. Schiff & Company will act on behalf of PDS
clients in the United States for compliance activities and clinical
studies.
PDS will be providing Regulatory and Quality Services to Schiff &
Company clients in Europe while Schiff & Company will be targeting
US based companies looking for local assistance in Europe. Support
would be provided in areas such as importation of clinical trials
materials, generation and submission of clinical trial applications,
ethics committee submissions, investigator brochures etc. PDS also
supplies a contract Qualified Person (QP) Release service for
US-based clients, and can act as local agent for medicines and
medical devices registered in Europe.
Dr Robert Schiff, CEO and President of Schiff & Company Inc, and
Dr Michael Gamlen, Managing Director of Pharmaceutical Development
Services (PDS), Nottingham UK, announced the alliance at a launch
event at Schiff’s New Jersey offices.
Dr Schiff said, “Our collaboration with PDS will provide
important local knowledge about the challenging requirements for
registering clinical trial materials and products in Europe, which
is their primary expertise. PDS will also be assisting in the
compilation of e-CTD (Common Technical Documents) documents on our
behalf using their state of the art e-CTD software.”
Michael Gamlen said, “Schiff & Company’s extensive worldwide
client base will offer us many opportunities to consolidate our
position as a leading European regulatory consultancy. We look
forward enormously to working with the new team. We are also very
excited about meeting old clients and new at the AAPS meeting in
November 2010 in New Orleans.”